請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19937
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李宣書(Hsuan-Shu Lee) | |
dc.contributor.author | Mei-Hui Wang | en |
dc.contributor.author | 王美惠 | zh_TW |
dc.date.accessioned | 2021-06-08T02:28:13Z | - |
dc.date.copyright | 2015-08-28 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-17 | |
dc.identifier.citation | [1] Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008;22(6):991-1008.
[2] Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, et al. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol 2014;60(6):1127-34. [3] Kaibori M, Ha-Kawa SK, Maehara M, Ishizaki M, Matsui K, Sawada S, et al. Usefulness of Tc-99m-GSA scintigraphy for liver surgery. Ann Nucl Med 2011;25(9):593-602. [4] Kim SH, Kang DR, Lee JG, Kim do Y, Ahn SH, Han KH, et al. Early predictor of mortality due to irreversible posthepatectomy liver failure in patients with hepatocellular carcinoma. World J Surg 2013;37(5):1028-33. [5] Mullin EJ, Metcalfe MS, Maddern GJ. How much liver resection is too much? Am J Surg 2005;190(1):87-97. [6] Pascoe A, Kerlin P, Steadman C, Clouston A, Jones D, Powell L, et al. Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation. Gut 1999;45(2):301-5. [7] Imura S, Shimada M, Utsunomiya T. Recent advances in estimating hepatic functional reserve in patients with chronic liver damage. Hepatol Res 2015;45(1):10-9. [8] Hoekstra LT, de Graaf W, Nibourg GA, Heger M, Bennink RJ, Stieger B, et al. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg 2013;257(1):27-36. [9] Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 1974;41(0):99-128. [10] Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982;51:531-54. [11] Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001;276(13):9626-30. [12] Tanaka Y, Chen C, Maher JM, Klaassen CD. Kupffer cell-mediated downregulation of hepatic transporter expression in rat hepatic ischemia-reperfusion. Transplantation 2006;82(2):258-66. [13] Child CG, Turcotte JG. Surgery and portal hypertension. In: CG C, editor. The liver and portal hypertension. Philadelphia: Saunders; 1964. p. 50-64. [14] Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60(8):646-9. [15] Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther 2005;22(11-12):1079-89. [16] Garcea G, Ong SL, Maddern GJ. Predicting liver failure following major hepatectomy. Dig Liver Dis 2009;41(11):798-806. [17] Nagashima I, Takada T, Okinaga K, Nagawa H. A scoring system for the assessment of the risk of mortality after partial hepatectomy in patients with chronic liver dysfunction. J Hepatobiliary Pancreat Surg 2005;12(1):44-8. [18] Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31(4):864-71. [19] Freeman RB, Jr., Wiesner RH, Roberts JP, McDiarmid S, Dykstra DM, Merion RM. Improving liver allocation: MELD and PELD. Am J Transplant 2004;4 Suppl 9:114-31. [20] Singal AK, Kamath PS. Model for End-stage Liver Disease. J Clin Exp Hepatol 2013;3(1):50-60. [21] O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97(2):439-45. [22] Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J Hepatol 1997;26(1):62-8. [23] Dhiman RK, Jain S, Maheshwari U, Bhalla A, Sharma N, Ahluwalia J, et al. Early indicators of prognosis in fulminant hepatic failure: an assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital criteria. Liver Transpl 2007;13(6):814-21. [24] Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986;6(4):648-51. [25] Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981;9(8):591-7. [26] Duseja A, Choudhary NS, Gupta S, Dhiman RK, Chawla Y. APACHE II score is superior to SOFA, CTP and MELD in predicting the short-term mortality in patients with acute-on-chronic liver failure (ACLF). J Dig Dis 2013;14(9):484-90. [27] Faybik P, Hetz H. Plasma disappearance rate of indocyanine green in liver dysfunction. Transplant Proc 2006;38(3):801-2. [28] Saito K, Ledsam J, Sourbron S, Hashimoto T, Araki Y, Akata S, et al. Measuring hepatic functional reserve using low temporal resolution Gd-EOB-DTPA dynamic contrast-enhanced MRI: a preliminary study comparing galactosyl human serum albumin scintigraphy with indocyanine green retention. Eur Radiol 2014;24(1):112-9. [29] Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 1997;84(9):1255-9. [30] Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356(15):1545-59. [31] de Graaf W, Hausler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, et al. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol 2011;54(4):738-45. [32] Paumgartner G. The handling of indocyanine green by the liver. Schweiz Med Wochenschr 1975;105(17 Suppl):1-30. [33] Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002;122(5):1715-20. [34] Wissler EH. Identifying a long standing error in single-bolus determination of the hepatic extraction ratio for indocyanine green. Eur J Appl Physiol 2011;111(4):641-6. [35] Berzigotti A, Reverter E, Garcia-Criado A, Abraldes JG, Cerini F, Garcia-Pagan JC, et al. Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. J Hepatol 2013;59(4):717-22. [36] Schneider PD. Preoperative assessment of liver function. Surg Clin North Am 2004;84(2):355-73. [37] de Graaf W, Bennink RJ, Vetelainen R, van Gulik TM. Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation. J Nucl Med 2010;51(5):742-52. [38] Lam CM, Fan ST, Lo CM, Wong J. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test. Br J Surg 1999;86(8):1012-7. [39] Wakabayashi H, Okada S, Maeba T, Maeta H. Effect of preoperative portal vein embolization on major hepatectomy for advanced-stage hepatocellular carcinomas in injured livers: a preliminary report. Surg Today 1997;27(5):403-10. [40] Moody FG, Rikkers LF, Aldrete JS. Estimation of the functional reserve of human liver. Ann Surg 1974;180(4):592-8. [41] Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236(4):397-406; discussion -7. [42] Tanabe G, Sakamoto M, Akazawa K, Kurita K, Hamanoue M, Ueno S, et al. Intraoperative risk factors associated with hepatic resection. Br J Surg 1995;82(9):1262-5. [43] Hemming AW, Gallinger S, Greig PD, Cattral MS, Langer B, Taylor BR, et al. The hippurate ratio as an indicator of functional hepatic reserve for resection of hepatocellular carcinoma in cirrhotic patients. J Gastrointest Surg 2001;5(3):316-21. [44] Fan ST, Lai EC, Lo CM, Ng IO, Wong J. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 1995;130(2):198-203. [45] Cherrick GR, Stein SW, Leevy CM, Davidson CS. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest 1960;39:592-600. [46] Redaelli CA, Dufour JF, Wagner M, Schilling M, Husler J, Krahenbuhl L, et al. Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg 2002;235(1):77-85. [47] de Graaf W, Bennink RJ, Heger M, Maas A, de Bruin K, van Gulik TM. Quantitative assessment of hepatic function during liver regeneration in a standardized rat model. J Nucl Med 2011;52(2):294-302. [48] Jansen PL, Chamuleau RA, van Leeuwen DJ, Schipper HG, Busemann-Sokole E, van der Heyde MN. Liver regeneration and restoration of liver function after partial hepatectomy in patients with liver tumors. Scand J Gastroenterol 1990;25(2):112-8. [49] Shoup M, Gonen M, D'Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003;7(3):325-30. [50] Mitsumori A, Nagaya I, Kimoto S, Akaki S, Togami I, Takeda Y, et al. Preoperative evaluation of hepatic functional reserve following hepatectomy by technetium-99m galactosyl human serum albumin liver scintigraphy and computed tomography. Eur J Nucl Med 1998;25(10):1377-82. [51] Akaki S, Okumura Y, Sasai N, Sato S, Tsunoda M, Kuroda M, et al. Hepatectomy simulation discrepancy between radionuclide receptor imaging and CT volumetry: influence of decreased unilateral portal venous flow. Ann Nucl Med 2003;17(1):23-9. [52] Ha-Kawa SK, Tanaka Y. A quantitative model of technetium-99m-DTPA-galactosyl-HSA for the assessment of hepatic blood flow and hepatic binding receptor. J Nucl Med 1991;32(12):2233-40. [53] Mei-Hui Wang, Chuan-Yi Chien, Ping-Yen Wang, Hung-Man Yu, Hsuan-Shu Lee, Lin W-J. The specificity and accuracy of 111In-hexavalent lactoside in estimating liver reserve and its threshold value for mortality in mice. journal of hepatology 2015;630:330-7. [54] Yang W, Mou T, Zhang X, Wang X. Synthesis and biological evaluation of (99m)Tc-DMP-NGA as a novel hepatic asialoglycoprotein receptor imaging agent. Appl Radiat Isot 2010;68(1):105-9. [55] Krishnamurthy S, Krishnamurthy GT. Technetium-99m-iminodiacetic acid organic anions: review of biokinetics and clinical application in hepatology. Hepatology 1989;9(1):139-53. [56] Loberg MD, Cooper M, Harvey E, Callery P, Faith W. Development of new radiopharmaceuticals based on N-substitution of iminodiacetic acid. J Nucl Med 1976;17(7):633-8. [57] Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998;339(17):1217-27. [58] Krishnamurthy S, Krishnamurthy GT, Lieberman D, Keeffe EB. Scintigraphic criteria for the diagnosis of obstructive hepatobiliary diseases with Tc-99m IDA. Clin Nucl Med 1988;13(10):704-9. [59] Krishnamurthy GT, Lieberman DA, Brar HS. Detection, localization, and quantitation of degree of common bile duct obstruction by scintigraphy. J Nucl Med 1985;26(7):726-35. [60] Ekman M, Fjalling M, Holmberg S, Person H. IODIDA clearance rate: a method for measuring hepatocyte uptake function. Transplant Proc 1992;24(1):387-8. [61] Bennink RJ, Dinant S, Erdogan D, Heijnen BH, Straatsburg IH, van Vliet AK, et al. Preoperative assessment of postoperative remnant liver function using hepatobiliary scintigraphy. J Nucl Med 2004;45(6):965-71. [62] Erdogan D, Heijnen BH, Bennink RJ, Kok M, Dinant S, Straatsburg IH, et al. Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test. Liver Int 2004;24(2):117-23. [63] Morell AG, Irvine RA, Sternlieb I, Scheinberg IH, Ashwell G. Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J Biol Chem 1968;243(1):155-9. [64] Lee RT, Lin P, Lee YC. New synthetic cluster ligands for galactose/N-acetylgalactosamine-specific lectin of mammalian liver. Biochemistry 1984;23(18):4255-61. [65] Lee YC, Lee RT. Neoglycoproteins as probes for binding and cellular uptake of glycoconjugates, . In: I. HM, editor. The Glycoconjugates. New York: Academic Press; 1982. p. 57-83. [66] Yang W, Zhang X, Liu Y. Asialoglycoprotein Receptor-Targeted Radiopharmaceuticals for Measurement of Liver Function. Current Medicinal Chemistry 2014;21:4-23. [67] Lawrence MS, Robert HC, Gregor HG. Amino acids and proteins.1986. [68] Abe M, Lai J, Kortylewicz ZP, Nagata H, Fox IJ, Enke CA, et al. Radiolabeled constructs for evaluation of the asialoglycoprotein receptor status and hepatic functional reserves. Bioconjug Chem 2003;14(5):997-1006. [69] Galli G, Maini CL, Orlando P, Cobelli C, Thomaset K, Deleide G, et al. A radiopharmaceutical for the study of the liver: 99mTc-DTPA-asialo-orosomucoid. II: Human dynamic and imaging studies. J Nucl Med Allied Sci 1988;32(2):117-26. [70] Galli G, Maini CL, Orlando P, Deleide G, Valle G. A radiopharmaceutical for the study of the liver: 99mTc-DTPA-asialo-orosomucoid. I: Radiochemical and animal distribution studies. J Nucl Med Allied Sci 1988;32(2):110-6. [71] Fiume L, Di Stefano G. Lactosaminated human albumin, a hepatotropic carrier of drugs. Eur J Pharm Sci 2010;40(4):253-62. [72] Kokudo N, Vera DR, Tada K, Koizumi M, Seki M, Matsubara T, et al. Predictors of successful hepatic resection: prognostic usefulness of hepatic asialoglycoprotein receptor analysis. World J Surg 2002;26(11):1342-7. [73] Kudo M, Todo A, Ikekubo K, Yamamoto K, Vera DR, Stadalnik RC. Quantitative assessment of hepatocellular function through in vivo radioreceptor imaging with technetium 99m galactosyl human serum albumin. Hepatology 1993;17(5):814-9. [74] Satoh K, Yamamoto Y, Nishiyama Y, Wakabayashi H, Ohkawa M. 99mTc-GSA liver dynamic SPECT for the preoperative assessment of hepatectomy. Ann Nucl Med 2003;17(1):61-7. [75] de Graaf W, van Lienden KP, van Gulik TM, Bennink RJ. (99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy. J Nucl Med 2010;51(2):229-36. [76] Li XF, Taki J, Kinuya S, Higuchi T, Konishi S, Hwang EH, et al. Asialoglycoprotein receptor concentration in tumor-bearing livers and its fate early after their sectorial resection. Ann Nucl Med 2003;17(6):489-93. [77] Stowell CP, Lee YC. The binding of d-glucosyl-neoglycoproteins to the hepatic asialoglycoprotein receptor. J Biol Chem 1978;253(17):6107-10. [78] Lee YC, Townsend RR, Hardy MR, Lonngren J, Arnarp J, Haraldsson M, et al. Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features. J Biol Chem 1983;258(1):199-202. [79] Lee RT, Lee YC. Affinity enhancement by multivalent lectin-carbohydrate interaction. Glycoconj J 2000;17(7-9):543-51. [80] Lee RT, Lee YC. Synthesis of peptide-based trivalent scaffold for preparation of cluster glycosides. Methods Enzymol 2003;362:38-43. [81] Merwin JR, Noell GS, Thomas WL, Chiou HC, DeRome ME, McKee TD, et al. Targeted delivery of DNA using YEE(GalNAcAH)3, a synthetic glycopeptide ligand for the asialoglycoprotein receptor. Bioconjug Chem 1994;5(6):612-20. [82] Hangeland JJ, Levis JT, Lee YC, Ts'o PO. Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleoside methylphosphonates covalently linked with a neoglycopeptide, YEE(ah-GalNAc)3. Bioconjug Chem 1995;6(6):695-701. [83] Hangeland JJ, Flesher JE, Deamond SF, Lee YC, Ts OP, Frost JJ. Tissue distribution and metabolism of the [32P]-labeled oligodeoxynucleoside methylphosphonate-neoglycopeptide conjugate, [YEE(ah-GalNAc)3]-SMCC-AET-pUmpT7, in the mouse. Antisense Nucleic Acid Drug Dev 1997;7(3):141-9. [84] Kwon AH, Inoue T, Ha-Kawa SK. Characterization of the asialoglycoprotein receptor under hypoxic conditions in primary cultured rat hepatocytes. J Nucl Med 2005;46(2):321-5. [85] Wu YT, Jiaang WT, Lin KG, Huang CM, Chang CH, Sun YL, et al. A new N-acetylgalactosamine containing peptide as a targeting vehicle for mammalian hepatocytes via asialoglycoprotein receptor endocytosis. Curr Drug Deliv 2004;1(2):119-27. [86] Lee RT, Wang MH, Lin WJ, Lee YC. New and more efficient multivalent glyco-ligands for asialoglycoprotein receptor of mammalian hepatocytes. Bioorg Med Chem 2011;19(8):2494-500. [87] Higgins GM, Anderson RM. Experimental Pathology of the Liver--Restoration of the Liver of the White Rat Following Partial Surgical Removal. Archives of Pathology 1931;12:186-202. [88] Mitchell C, Willenbring H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc 2008;3(7):1167-70. [89] Mitchell C, Willenbring H. Addendum: A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc 2014;9(6). [90] Wang MH, Lin WJ, Yu HM, Chien CY, Wang PY. Liver-receptor imaging injection, dispensing method and pharmaceutical composition thereof. TWI392511. Taiwan: Institute of Nuclear Energy Research; 2013. [91] Yu HM, Wang MH, Chen JT, Lin WJ. Labelling of peptide derivative with In-111 for receptor imaging. J Label Compd Radiopharm 2010;53 406-89. [92] Bennink RJ, Tulchinsky M, de Graaf W, Kadry Z, van Gulik TM. Liver function testing with nuclear medicine techniques is coming of age. Semin Nucl Med 2012;42(2):124-37. [93] Whitby LG, Smith AF, Beckett GJ, Walker SW. Chapter 8 Liver disease. Lecture notes on clinical biochemistry. Fifth ed: Blackwell Scientific Publications; 1993. p. 105. [94] Washino K, Kurami M. Radioactive matallic element-labelled high molecular compound useful in nuclear medicine. US 5118792 1992. [95] Sawamura T, Nakada H, Hazama H, Shiozaki Y, Sameshima Y, Tashiro Y. Hyperasialoglycoproteinemia in patients with chronic liver diseases and/or liver cell carcinoma. Asialoglycoprotein receptor in cirrhosis and liver cell carcinoma. Gastroenterology 1984;87(6):1217-21. [96] Casey CA, McVicker BL, Donohue TM, Jr., McFarland MA, Wiegert RL, Nanji AA. Liver asialoglycoprotein receptor levels correlate with severity of alcoholic liver damage in rats. J Appl Physiol 2004;96(1):76-80. [97] Li Y, Huang G, Diakur J, Wiebe LI. Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv 2008;5(4):299-302. [98] Pricer WE, Jr., Hudgin RL, Ashwell G, Stockert RJ, Morell AG. A membrane receptor protein for asialoglycoproteins. Methods Enzymol 1974;34:688-91. [99] Wang MH, Yu HM, Chien CY, Lee RT, Lee YC, Lin WJ. A novel and efficient liver targeting agent: biodistribution, pharmacokinetics, SPECT/CT imaging, and autoradiography. Eur J Nucl Med Mol Imaging 2009;36 (S2):S470. [100] Yan H, Wu W, Yang Y, Wu Y, Yang Q, Shi Y. A novel integrated Model for End-Stage Liver Disease model predicts short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure patients. Hepatol Res 2014. [101] O'Grady J. Timing and benefit of liver transplantation in acute liver failure. J Hepatol 2014;60(3):663-70. [102] Muller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats--usefulness and reliability of this animal model. Exp Pathol 1988;34(4):229-36. [103] Porter WR, Gudzinowicz MJ, Neal RA. Thioacetamide-induced hepatic necrosis. II. Pharmacokinetics of thioacetamide and thioacetamide-S-oxide in the rat. J Pharmacol Exp Ther 1979;208(3):386-91. [104] Bruck R, Aeed H, Shirin H, Matas Z, Zaidel L, Avni Y, et al. The hydroxyl radical scavengers dimethylsulfoxide and dimethylthiourea protect rats against thioacetamide-induced fulminant hepatic failure. J Hepatol 1999;31(1):27-38. [105] Moreira E, Fontana L, Periago JL, Sanchez De Medina F, Gil A. Changes in fatty acid composition of plasma, liver microsomes, and erythrocytes in liver cirrhosis induced by oral intake of thioacetamide in rats. Hepatology 1995;21(1):199-206. [106] Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, et al. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002;36(1):12-21. [107] Kornek M, Raskopf E, Guetgemann I, Ocker M, Gerceker S, Gonzalez-Carmona MA, et al. Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. J Hepatol 2006;45(3):370-6. [108] Tarcin Orhan, Basaranoglu Metin, Tahan Veysel, Tahan Gulgun, Sucullu llker, Yilmaz Nevin, et al. Time course of collagen peak in bile duct-ligated rats. BMC Gastroenterology 2011;11. [109] NHessien M. H., El-Sharkawi I. M., El-Barbary A. A., El-Beltagy D. M., N. S. Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and schistosomal infection in mice. BMC Gastroenterology 2010;10. [110] Kisseleva T., Cong M., Paik Y., Scholten D., Jiang C., Benner C., et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America 2012;109 (24):9448-53. [111] Tang XN, Berman AE, Swanson RA, Yenari MA. Digitally quantifying cerebral hemorrhage using photoshop and image J. Journal of Neuroscience Methods 2010; 190(2 ). [112] Jonker AM, Dijkhuis FW, Boes A, Hardonk MJ, Grond J. Immunohistochemical study of extracellular matrix in acute galactosamine hepatitis in rats. Hepatology 1992;15(3):423-31. [113] Kao HW, Chen CL, Chang WY, Chen JT, Lin WJ, Liu RS, et al. (18)F-FBHGal for asialoglycoprotein receptor imaging in a hepatic fibrosis mouse model. Bioorg Med Chem 2013;21(4):912-21. [114] Chang WY, Kao HW, Wang HE, Chen JT, Lin WJ, Wang SJ, et al. Synthesis and biological evaluation of technetium-99m labeled galactose derivatives as potential asialoglycoprotein receptor probes in a hepatic fibrosis mouse model. Bioorg Med Chem Lett 2013;23(23):6486-91. [115] Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010;99(3):306-14. [116] Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85(3):294-310. [117] Young JF, Luecke RH, Pearce BA, Lee T, Ahn H, Baek S, et al. Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data. J Toxicol Environ Health A 2009;72(8):527-40. [118] Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46(6):1023-7. [119] Loevinger R, Budinger T, Watson E. MIRD Primer For Absorbed Dose Calculations,. New York: Society of Nuclear Medicine; 1988. [120] Lam K, Chan C, Done SJ, Levine MN, Reilly RM. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. Nucl Med Biol 2015;42(2):78-84. [121] Shannon RS, Minakshi N, Nihal A. Dose translation from animal to human studies revisited. FASEB J 2008;22(3):659-61. [122] Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. In: U.S. Food and Drug Administration, Center for Drug Evaluation and Research CfBEaR, editors. Rockville, Maryland, USA2002. [123] Ono K, Hiraoka T, Ono A, Komatsu E, Shigenaga T, Takaki H, et al. Low-dose CT scan screening for lung cancer: comparison of images and radiation doses between low-dose CT and follow-up standard diagnostic CT. Springerplus 2013;2:393. [124] Prosch H. Implementation of lung cancer screening: promises and hurdles. Transl Lung Cancer Res 2014;3(5):286-90. [125] Reilly RM. Monoclonal antibody and peptide-targeted radiotherapy of cancer. NJ: john Wiley & Sons 2010. [126] Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47(5):885-95. [127] Chang TM, Chang CL. Hepatic uptake of asialoglycoprotein is different among mammalian species due to different receptor distribution. Biochim Biophys Acta 1988;942(1):57-64. [128] Park EI, Baenziger JU. Closely related mammals have distinct asialoglycoprotein receptor carbohydrate specificities. J Biol Chem 2004;279(39):40954-9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19937 | - |
dc.description.abstract | 去唾液酸醣蛋白受體(Asialoglycoprotein receptor, ASGPR)存在肝細胞表面可以辨認醣蛋白的半乳醣基。本論文研究涵蓋兩部分,第一部分主要涵蓋第二-第四章節,係利用ASGPR可結合半乳醣基的特性,發展銦-111-乙二烯三胺五醋酸-六聚乳醣(111In diethylene triamine pentaacetic acid hexa-lactoside, 111In-DTPA-HL)造影標記與測量肝臟殘存功能的造影術;第二部分在第五章節,係比較銦-111-乙二烯三胺五醋酸-三聚半乳醣胺乙酸(111In diethylene triamine pentaacetic acid tri-galactosamine, 111In-DTPA-triGalNAc)和111In-DTPA-HL放射標誌與造影的必要條件。
第一部分實驗方法包括111In-DTPA-HL評估肝貯存量的專一性、靈敏度、準確度與閥值試驗,以及臨床前藥物動力學、組織分布、輻射劑量評估與延伸性急毒性試驗。本文以相對於正常鼠肝臟放射吸收讀值為肝貯存量。實驗結果顯示111In-DTPA-HL 73.64 +/- 7.11%聚積在正常鼠肝臟,而幾乎不存在肝癌區塊;以去唾液酸胎球蛋白(asialofetuin) 作為競爭試驗之抑制劑,當ASGPR受asialofetuin抑制,僅低於0.41 +/- 0.04% 111In-DTPA-HL存在肝臟。以20-80%部分切肝鼠進行造影,肝臟造影值和肝剩餘重量呈正相關(R2=0.8548),說明其造影具一定準確度。以对羥基乙酰苯胺(acetaminophen)誘發急性肝炎,則相對正常肝貯存量只剩下19-45% ,且若是肝貯存量低於25%以下,一周內小鼠會死亡。藥動試驗顯示,111In-DTPA-HL 3-5分鐘快速且大量聚積在肝,半小時後代謝;因為有很好的肝標靶特性,由動物試驗推估成人劑量以單光子放射斷層掃描術可低到1 mCi,如此全身暴露劑量可減至1.1 mSv;由於單劑18F-FDG輻射吸收劑量(7-14 mSv)迄今並沒有任何毒性報導,如此推估111In-DTPA-HL也應該不致有輻射毒性或相關併發症。我們進一步發現單一肝臟細胞的放射活度吸收,在大小鼠是一樣的,但若以相同劑量(Ci)對肝臟吸收作圖,大鼠有高於小鼠4倍差異,也就是說大小鼠單一肝細胞在ASGPR的吞噬活性是相同的,但大鼠有高於小鼠4倍的受體數;這和衛福部食藥署指引所提出的大小鼠體表面積差異是相同的。臨床病理與組織病理試驗顯示以高於成人劑量10000倍的DTPA-HL沒有毒性反應,表示此藥劑具有高安全性。 第二部分的實驗方法包括111In-DTPA-triGalNAc和111In-DTPA-HL的合成、放射標誌與造影。實驗結果顯示以DTPA-HL/111In莫耳數比為10的條件,即可產製放射化學純度為100% 的111In-DTPA-HL,且比活度大於1000 uCi/ug。然而111In-DTPA-triGalNAc卻需要加一段六碳長鏈才能達到> 90%放射化學純度。於造影試驗,無論是111In-DTPA-HL或111In -DTPA-triGalNAc在大小鼠皆有肝標靶特性,但大小鼠需求之放射比活度不同。大鼠造影111In-DTPA-triGalNAc比活度即使低至4.6 uCi/ug仍可以看見肝臟有吸收,但做小鼠造影,111In-DTPA-triGalNAc比活度必須高於9.2 uCi/ug。 總結,111In-DTPA-HL似乎是一個良好、專一有準確靈敏的功能性肝貯存量的評估技術。依小鼠試驗,決定個體是否得以存活的肝貯存量閥值是25%。 | zh_TW |
dc.description.abstract | The asialoglycoprotein receptor (ASGPR) on hepatocyte membranes recognizes the galactose residues of glycoproteins. There are two aims in this dissertation. One is to develop 111In-DTPA-hexa lactoside (111In-DTPA-HL) imaging biomarker and ASGPR scintigraphy for estimation of liver reserve (Chapters 2-4). The other is to compare 111In-DTPA-HL and 111In-DTPA- triGalNAc in the requirement of radiolabeling and imaging (Chapter 5).
The result indicates a total of 73.64+/-7.11% of the injection dose accumulated in the normal liver tissue region, and radioactivity was barely detected in the hepatoma region. When asialoglycoprotein receptor was blocked using asialofetuin, a known ASGPR blockade, less than 0.41+/-0.04% of the injection dose was detected as background in the liver. Asialoglycoprotein receptor imaging data revealed a linear correlation between 111In-DTPA-HL binding and residual liver mass (R2=0.8548) in 20-80% of partially hepatectomized mice, demonstrating the accuracy of 111In-DTPA-HL imaging for measuring the functional liver mass. Asialoglycoprotein receptor imaging data in mice with liver failure induced using 600 mg/kg acetaminophen revealed 19-45% liver reserve relative to normal mice and a fatal threshold value of 25% liver reserve. The pharmacokinetics study showed 111In-DTPA-HL rapidly accumulated and largely concentrated in liver in 3-5 min, and metabolized gradually after 0.5 h. Based on the mice dose 4 uCi/20g in parallel-hole collimator type microSPECT, we predict 1 mCi of 111In-DTPA-HL should be suitable for first-in-human. The estimated total body dose was 2.98E-02 mSv/MBq which corresponds to a whole body dose of 1.1 mSv per 1 mCi administered dose. Since 18F-FDG ( 7-14 mSv each administration) is used routinely in clinical scans with no reports of toxicities, use of 111In-DTPA-HL should result in no toxicity or complications. There is no ASGPR endocytic activity discrimination in hepatocytes between rat and mouse. The observed difference in imaging comes from the difference of their total body surface area. There is no toxicity detected in rat at more than 10000-times the human dose. As to the comparative radiochemistry and microSPECT/CT imaging behavior of 111In-DTPA-HL and 111In-DTPA-triGalNAc, both of 111In-DTPA-HL and 111In-DTPA triGalNAc showed liver targeting characteristics either in mouse or in rat. However, they behaved quite different in radiochemistry. The 111In-DTPA-HL quite easily attained 100% radiochemical purity and more than 1000 uCi/ug specific radioactivity under room temperature with 10:1 molar ratio of ligand to 111In. However, 111In-triGalNAc needed heating to enhance the radiochemical yield unless extended with a C6 long arm. Interestingly, we found 111In-triGalNAc with 9.2 uCi/ug could be used for liver imaging either for rat and mouse; however, 4.6 uCi/ug specimen only could be used for liver imaging for rat, but not mouse. In conclusion, the 111In-DTPA-HL imaging method appears to be a good, specific visual sensitive and quantitative predictor of functional liver reserve. The diagnostic threshold for survival was at 25% liver reserve in mice. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T02:28:13Z (GMT). No. of bitstreams: 1 ntu-104-D00642003-1.pdf: 2394012 bytes, checksum: b7280a92f2f9c1e37ae403a52236eb5a (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 中文摘要 i
Abstract iii Contents v List of Figures x List of Tables xii Abbreviations xiii Chapter 1 Introduction 1 1.1 The importance of pre-operative evaluation of liver reserve 1 1.2 Background of liver reserve 2 1.3 Current indicators of liver reserve 3 1.3.1 Serum bilirubin 3 1.3.2 Child-Pugh score 4 1.3.3 MELD 4 1.3.4 King’s College Hospital Criteria 5 1.3.5 Clichy criteria 5 1.3.6 Acute Physiology and Chronic Health Evaluation score 6 1.3.7 Albumin and prothrombin time 6 1.3.8 Indocyanine green (ICG) clearance test 6 1.3.9 Galactose elimination capacity test 8 1.3.10 Liver volumetry by computed tomography (CT) 8 1.3.11 99mTc-galactosyl serum albumin scintigraphy 9 1.3.12 99mTc-mebrofenin hepatobiliary scintigraphy 9 1.4 Why we need to develop a new measurement method for functional liver reserve 10 1.5 Introduction of asialoglycoprotein receptor and related imaging agents 11 1.5.1 Protein-based ASGPR imaging agents 12 1.5.2 Peptide-based ASGPR imaging agents 14 1.6 Design strategy of peptide-based ASGPR imaging agents in our study 16 Chapter 2 The specificity and accuracy of 111In-DTPA-HL in estimating liver reserve and its threshold value for mortality in mice 19 2.1 Specific aim of specificity and accuracy studies 19 2.2 Materials and methods 20 2.2.1 Animals and cells 20 2.2.2 Animal models 20 2.2.3 Synthesis of DTPA-HL 21 2.2.4 Radiolabeling of 111In-DTPA-HL 22 2.2.5 111In-DTPA-HL scintigraphy 22 2.2.6 Autoradiography 23 2.2.7 Affinity blocking study of 111In-DTPA-HL scintigraphy using asialofetuin 24 2.2.8 Organ pharmacokinetics of 111In-DTPA-HL in mice 24 2.2.9 Statistical analysis 24 2.3 Results 25 2.3.1 Evidence of targeting of 111In-DTPA-HL 25 2.3.2 Image specificity in differentiating between hepatocellular carcinoma and normal liver 25 2.3.3 Image accuracy when measuring different functional liver masses 26 2.3.4 Threshold study of liver failure 26 2.4 Discussion 27 Chapter 3 Asialoglycoprotein Biomarker Imaging Used as a Sensitive Technology for Evaluation of Liver Reserve in Rodents 41 3.1 Specific aim of sensitivity study in mice with liver fibrosis 41 3.2 Methods 42 3.2.1 Strategy to induce liver fibrosis in rodents 42 3.2.2 Animals 42 3.2.3 Animal models 43 3.2.4 Pathological staining and clinical biochemical assays 44 3.3 Results 45 3.3.1 Immunohistochemical staining of hepatocytes with anti-ASGPR on healthy mice, woodchuck hepatitis virus-infected Marmota monax and TAA-induced fibrosis mice 45 3.3.2 Pathological staining of fibrosis and related biochemical tests 46 3.3.3 Radioactivity uptake at various severities of chronic hepatitis 46 3.4 Discussion 47 Chapter 4 Pharmacokinetics, radiation dosimetry and toxicology studies of 111In-DTPA-HL in normal mice 59 4.1 Specific aim of pharmacokinetics, dosimetry and toxicology studies 59 4.2 Methods 59 4.2.1 Biodistribution and pharmacokinetics of 111In-DTPA-HL in mice 59 4.2.2 Internal radiation dose calculation 61 4.2.3 Extended acute toxicity 62 4.2.4 Statistical analysis 63 4.3 Results 64 4.3.1 Pharmacokinetic and biodistribution studies 64 4.3.2 Internal radiation dosimetry projections 65 4.3.3 Extended acute toxicology 66 4.4 Discussion 67 Chapter 5 Characterization of 111In-triGalNAc and 111In-DTPA-HL and species-related sensitivity differences in ASGPR imaging between rats and mice 79 5.1 Specific aim 79 5.2 Methods 79 5.2.1 Cells 79 5.2.2 Cellular uptake of 111In-DTPA-HL by Clone 9 and FL83B hepatocytes 79 5.2.3 Affinity binding of 111In-DTPA-HL and hepatocytes with an asialofetuin blockade 80 5.2.4 Cell toxicity test 80 5.2.5 Establishment of liver absorption curve using different doses of 111In-DTPA-HL 81 5.2.6 Synthesis of multivalent glycopeptides and 111In-radiolabeled compounds 81 5.2.7 Study of the effect of the triGalNAc/111In molar ratio on the radiochemical yield 82 5.2.8 Radio-instant thin-layer chromatography 82 5.2.9 microSPECT/CT images with 111In-DTPA-triGalNAc of different specific radioactivities 83 5.3 Results 84 5.3.1 Physical and chemical properties of 111In- DTPA-triGalNAc 84 5.3.2 Radiochemical purity of 111In-DTPA-HL 85 5.3.3 Cellular binding assay between mice and rats 86 5.3.4 Properties of 111In-DTPA-long arm triGalNAc 87 5.3.5 Characterization of 111In-DTPA-HL 87 5.3.6 Toxicity evaluation on cellular hepatocytes 88 5.4 Discussion 89 Chapter 6 Conclusions 103 Chapter 7 Perspectives 104 Reference 105 | |
dc.language.iso | en | |
dc.title | 以去唾液酸醣蛋白受體造影術測量鼠類肝臟殘存功能 | zh_TW |
dc.title | Measurement of Liver Reserve in Rodents by an Asialoglycoprotein Receptor Imaging | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 李伯皇(Po-Huang Lee),林武智(Wuu-Jyh Lin),王信二(Hsin-Ell Wang),林淑萍(Shwu-Bin Lin) | |
dc.subject.keyword | 去唾液酸醣蛋白受體,肝貯存量,銦-111-乙二烯三胺五醋酸-六聚乳醣造影術,肝癌,肝纖維化,急性肝衰竭,切肝術, | zh_TW |
dc.subject.keyword | asialoglycoprotein receptor,liver reserve,111In DTPA-hexavalent lactoside scintigraphy,liver cancer,liver fibrosis,acute liver failure,hepatectomy, | en |
dc.relation.page | 121 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2015-08-17 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 生物科技研究所 | zh_TW |
顯示於系所單位: | 生物科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 2.34 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。